Myocardial infarction (MI) leads to significant cardiomyocyte cell death. These specialized cells are not replaced in substantial numbers after injury, leading to disproportionate thinning of the heart wall and severely impaired cardiac function. Moreover, cardiac fibroblasts, which form a significant proportion of the heart, are expanded further, leading to excessive fibrosis and scar formation. Fibrotic remodeling of the injured myocardium negatively impacts contractility and electric conduction, which over time causes a further deterioration in cardiac function.1

Several strategies are being actively pursued in cardiac regenerative medicine. Replacing lost cardiomyocytes by injecting cardiac progenitors, cardiospheres, or cardiac myocytes derived from inducible pluripotent stem cells (iPS/ESCs) has been researched intensively. Others have focused instead on the cardiomyocytes by enabling them to enter cell cycle to replicate and proliferate as a means to generate new muscle cells. However, these approaches, although encouraging, face significant challenges. Recently, much excitement has been turned to the cardiac fibroblast.
population in the scar tissue with a view to turning these cells into cardiomyocytes. Taking cues from heart developmental programs, direct reprogramming of fibroblasts to cardiomyocytes has been achieved recently by specific combinations of transcription factors and microRNAs (miRNAs). In this review, we discuss the role of miRNAs in cardiac development, as well as in indirect and direct cardiac reprogramming. Based on this scientific knowledge, we discuss the strategy of targeting miRNAs for cardiac regeneration therapy.

MiRNA Biology

MiRNAs are small noncoding RNAs belonging to a class of small silencing RNAs that are critically important in the posttranscriptional regulation of genes. Indeed, most mammalian miRNAs are targets of miRNAs. MiRNAs have been demonstrated to play an important role in the differentiation and development of many cells and tissues, including the heart. Moreover miRNAs are important for stem cell differentiation, as well as indirect and direct reprogramming to multiple lineages.

The RNA polymerase II enzyme transcribes miRNAs and the resulting transcript is known as a primary-miRNA. The primary-miRNA is ~1000 nucleotides in length, possesses a 5’ cap, a middle stem loop structure, and a 3’ polyadenylated tail. Primary-miRNAs are processed further into pre-miRNAs by the Microprocessor complex, a component of the Microprocessor complex, cleaves the 5’ cap and 3’ poly (A) tail leaving an ~65 bp stem loop structure containing the mature miRNA. After cleavage by Drosha, the pre-miRNA is transported from the nucleus into the cytoplasm. Once in the cytoplasm, the pre-miRNA is cleaved further by the RNase III-type endonuclease Dicer (double-stranded RNA-specific endoribonuclease) into a smaller fragment containing the mature miRNA. In humans, the Dicer-generated small dsRNA fragment containing the mature miRNA is loaded onto one of 4 Argonaute (Ago) proteins, Ago 1–4, an action facilitated a heat shock cognate—heat shock protein 90 complex. Within this complex, which is named the pre-RNA-induced silencing complex, processing occurs to generate the final single-stranded mature miRNA. The single-stranded miRNA, associated with Ago 1–4, constitutes the mature RNA-induced silencing complex. This is the final functional unit that mediates post-transcriptional repression of a target.

MiRNAs in Cardiac Development and Function

Cardiac-specific deletions of Dicer gave the first evidence of a role of miRNAs in cardiac development. Deletion of Dicer in Nkx2-5 (homeobox protein Nkx2-5) cardiac progenitor cells induced development defects in the heart, such as cardiac edema and poorly developed ventricular myocardium, leading to embryonic lethality at E12.5 because of cardiac failure. The use of an alternative allele for the Nkx2.5-Cre transgene, which allowed mutant mice to survive beyond E13.5, highlighted additional role for Dicer in cardiac outflow tract alignment and chamber septation. Using an α-myosin heavy chain (αMHC) promoter to delete Dicer expression at a later stage of cardiac development caused impairment of cardiac function through dysregulated cardiac contractile protein expression, disrupted sarcomeric structure, and disarray of myofibers. Mice quickly developed dilated cardiomyopathy and heart failure with lethality observed within 4 days of birth. Similarly, using a tamoxifen-inducible αMHC-Cre, another group depleted Dicer in the postnatal heart. Loss of Dicer in juveniles resulted in mild cardiac remodeling and premature death within 1 week, whereas deletion in adults led to severe hypertrophy, myofiber disarray, ventricular fibrosis, and reactivation of a fetal gene transcription program.

The study of individual mature miRNAs has demonstrated their importance in cardiac development. MiRNA-1 is produced from 2 loci. The 2 mature miRNAs are called miRNA-1-1 and miRNA-1-2 to distinguish them from each other. MiRNA-1-1 and miRNA-1-2, cotranscribed with miRNA-133-a2 and miRNA-133-a1, respectively, are expressed specifically in cardiac and skeletal muscle with expression increasing substantially from E8.5 to adulthood. Transcription of miRNA-1/miRNA-133 in heart and skeletal muscle is regulated by serum response factor, myocardin, myogenic differentiation 1, and myocyte enhancer factor (MeF2) transcription factors. Expression of serum response factor is repressed by miRNA-133 in myoblasts, suggesting a negative regulatory loop.

Overexpression of miRNA-1 in the developing mouse heart inhibits proliferation of ventricular cardiomyocytes. Developmental arrest occurs at E13.5 secondary to thinning of ventricle walls and heart failure. Heart- and neural crest derivative–expressed (Hand)-2, a direct target of miRNA-1, may mediate these effects. Similar findings have been observed in Xenopus, suggesting miRNA-1 is important for the development of the vertebrate heart.

MiRNA-1-2 deletion in mice induces a range of phenotypes. Approximately half of the miRNA-1-2 null mice died between E15.5 and birth from severe ventricular septation defects. The surviving miRNA-1-2 null mice possessed thickened cardiac walls arising from increased cardiomyocyte proliferation. Moreover, conduction defects were observed because of de-repression of Irx5, and several null mice died within 2 to 3 months from dilatation of the heart and ventricular dysfunction. MiRNA-1-1 null mice are similar, with partial lethality, mild ventricular dilation, and conduction defects all being observed.
Partially penetrant lethality in single miRNA-1-1 or miRNA-1-2 null mice may reflect compensation by the remaining miRNA-1. To elucidate the role of miRNA-1, double mutant mice for miRNA-1-1 and miRNA-1-2 (miRNA-1 double knockout [dKO]) were recently engineered by 2 groups.\textsuperscript{44,45} Heidersbach et al\textsuperscript{46} found that miRNA-1 dKO mice died uniformly before P10 because of severe cardiac dysfunction, including ventricular septal defects, heart chamber dilatation, abnormal conduction, and sarcomere disruption. In the miRNA-1 dKO mice, Telokin, the smooth muscle–restricted inhibitor of myosin light chain-2 phosphorylation, was ectopically expressed in the myocardium. Telokin was found to be a direct target of miRNA-1, suggesting that miRNA-1 promotes cardiac development and sarcomeric organization by repressing the smooth muscle gene program.\textsuperscript{44} Similarly, miRNA-1 dKO mice generated by Wei et al\textsuperscript{46} died by P17 from heart dilatation, an increase in cardiac mass arising from elevated cardiomyocyte proliferation, and sarcomeric defects. However, ventricular septal defects were not observed. In the miRNA-1 dKO mice, increased expression of the nuclear receptor estrogen-related receptor 2β, a direct miRNA-1 target, activated a fetal gene program, which included the expression of fetal sarcomere-associated genes. Expressing estrogen-related receptor 2β in heart tissue mimicked the miRNA-1 dKO phenotype, further validating the model.\textsuperscript{46}

The differences between these 2 studies may reflect that miRNA-1 controls heart development through multiple pathways, the methods used to generate the null mice, or genetic background. MiRNA-133 is cotranscribed with miRNA-1 and shares a commonality of function during heart development. Overexpression of miRNA-133 in Xenopus induces defects in cardiac looping and chamber formation.\textsuperscript{42} Zebrafish regenerate their hearts after severe injury by increasing cardiomyocyte proliferation. Interestingly, transgenic expression of miRNA-133 inhibited this process in part by targeting the QRS complex.\textsuperscript{46} To gain further insights into the role of miRNA-133 in the development of the mammalian heart, both miRNA-133a1 and miRNA-133a2 were ablated in mice (miRNA-133 dKO). The phenotype of the miRNA-133 dKO mice was found to be somewhat similar to that of the miRNA-1 dKO. Approximately half of miRNA-133 dKO mice died postnatally because of ventricular septal defects, increased cardiomyocyte proliferation, and aberrant expression of smooth muscle genes.\textsuperscript{47} Surviving mutants displayed severe cardiac dysfunction with death from heart failure within 6 months. The miRNA-133 dKO phenotype was attributed in part to the increased expression of cyclinD2, a negative regulator of cell cycle, and serum response factor, a coactivator of smooth muscle genes.\textsuperscript{47} The high level of miRNA-133 expression in the adult heart may also be important for homeostasis of the organ because knockdown of miRNA-133 promoted hypertrophy in one report and overexpression of miRNA-133 inhibits hypertrophic stimuli.\textsuperscript{48,49} Calcineurin levels increase during cardiac hypertrophy, and this protein may act in a reciprocal fashion with miRNA-133. Overexpression of miRNA-133 inhibited calcineurin expression, and inhibition of calcineurin by cyclosporin-A prevented miRNA-133 downregulation in a hypertrophic model.\textsuperscript{50}

Mice with a combined deletion of the 2 miRNA-1/miRNA-133a clusters (miRNA-1/133 dKO) have also been generated.\textsuperscript{51} Genetic ablation of either cluster was not detrimental to mice development and survival. However, deletion of both miRNA-1/133a clusters was embryonically lethal. MiRNA-1/133 dKO mice displayed severe cardiac defects with thinning of ventricular walls and decreased cardiomyocyte proliferation. These effects were associated with increased smooth muscle gene expression, notably that of the smooth muscle regulator myocardin. Overexpression of myocardin recapitulated many aspects of the miRNA-1/133 dKO phenotype, arresting the developing cardiomyocytes in an immature state. Interestingly, myocardin activated the transcription of both miRNA-1/133a clusters, suggesting that a negative feedback loop exists to restrict smooth muscle gene expression and to promote cardiomyocyte maturation.\textsuperscript{51}

In mammals, cardiomyocyte contraction depends on 2 MHC proteins. The faster contracting isoform αMHC is expressed predominantly in adult mouse heart, whereas the embryonic heart expresses the slower contracting isoform βMHC.\textsuperscript{52} In humans, βMHC expression continues into adulthood; however, hypertrophy induces the β form in humans and rodents alike.\textsuperscript{53} Expression of α- and β-MHC isoforms is controlled by miRNA-208a, miRNA-208b, and miRNA-499\textsuperscript{54–56}. MiRNA-208a and miRNA-208b are encoded in an intron of the αMHC and βMHC gene, respectively. Mice null for miRNA-208a are viable and show no changes in heart structure ≤20 weeks. However, a progressive decrease in heart contractility was observed from 2 months postbirth, and this was concomitant with aberrant expression of fast skeletal muscle contractile proteins.\textsuperscript{54} Despite the lack of gross structural changes in heart structure in miRNA-208a null mice, there are significant electric conduction defects, with a lack of P waves (atrial depolarization) preceding QRS complexes (right and left ventricular depolarization) and significantly prolonged PR intervals (the interval from where the P wave begins until the beginning of the QRS complex).\textsuperscript{55} Further underlying a role in the heart’s electric conduction system, overexpression of miRNA-208a induced arrhythmia.\textsuperscript{55} MiRNA-208a null mice fail to show a hypertrophic response after such stimuli as transverse aortic banding and calcineurin.\textsuperscript{54,55} Moreover, there was no increase in βMHC expression,\textsuperscript{54,55} indicating that miRNA-208a controls expression of this MHC isoform. Thyroid signaling is important in the switch of MHC expression after birth, activating expression of αMHC, whereas inhibiting the expression of βMHC.\textsuperscript{57} MiRNA-208a was found to be important in this process by directly targeting thyroid hormone receptor–associated protein 1.\textsuperscript{54}

MiRNA-208a not only controls the expression of βMHC, but also that of the closely related βMHC isoform Myh7b.\textsuperscript{56} Both βMHC and Myh7b are slow myosins; the genes for these proteins contain intronic miRNAs, miRNA-208b, and miRNA-499, respectively. These miRNAs are important in the specification of the identity of muscle fibers by stimulating slow myofiber gene programs at the expense of those that control fast myofiber gene expression.\textsuperscript{56} Mice lacking the miRNA-499 gene have no obvious developmental defects.\textsuperscript{56} However, overexpression of miRNA-499 promotes hypertrophy.\textsuperscript{56,59}
The mammalian heart increases in size dramatically during embryonic development predominantly via an increase in cardiomyocyte numbers. After birth, mammalian cardiomyocytes exit the cell cycle, and this has a negative impact on cardiac regeneration after injury.\(^{60-62}\) In contrast to mammals, lower vertebrates, such as zebrafish, retain the ability to regenerate their hearts throughout life. In the case of the zebrafish, this natural ability is particularly robust because complete cardiac regeneration has been observed even when ~20% of the ventricular myocardium was removed.\(^{63}\) Cardiomyocyte dedifferentiation followed by re-entry into the cell cycle underlies this process.\(^{64}\) MiRNAs are critically important for cardiomyocyte proliferation. In a recent study, cardiac regeneration in the zebrafish was found to be dependent on a decrease in the levels of miRNA-99/100 and Let-7a/c\(^65\). Interestingly, this did not occur in the murine heart after injury. When the authors forcibly reduced miRNA-99/100 and Let-7a/c expression after MI in the mouse recovery was observed, indicating a species conserved miRNA program for cardiac regeneration.\(^{62,65}\) The miRNA-17-92 cluster has also been shown to be important for cardiomyocyte proliferation. Overexpression of this miRNA cluster induced cardiomyocyte proliferation in neonatal and adult hearts. Interestingly, transgenic overexpression of miRNA-17-92 in adult cardiomyocytes protected the heart from MI-associated injury. The miRNA-17-92 cluster was found to reduce the expression of phosphatase and tensin homolog, a proliferation repressor.\(^{66}\) Studies have demonstrated that withdrawal of cardiomyocytes from the cell cycle is dependent on specific miRNAs. A microarray analysis for miRNAs, differentially regulated between P1 and P10, the point at which mouse cardiomyocytes exit the cell cycle, identified miRNA-195 as the most highly upregulated miRNA. Overexpression of this miRNA cluster induced cardiomyocyte proliferation in neonatal and adult hearts. Interestingly, transgenic overexpression of miRNA-17-92 in adult cardiomyocytes protected the heart from MI-associated injury. The miRNA-17-92 cluster was found to reduce the expression of phosphatase and tensin homolog, a proliferation repressor.\(^{66}\)

**MiRNAs and the Formation of iPS Cells**

iPS are an important source of cells for cardiac regeneration because they can form all of the cardiovascular cell types on differentiation.\(^{72,73}\) Indeed, intramyocardial delivery of iPS after MI has been shown to restore contractile performance, cardiac tissue, and ventricular wall thickness.\(^{74-76}\) The first iPS cells were generated when Takahashi and Yamanaka overexpressed Oct4, Sox2, Klf4, and cMyc (OKSM) in fibroblasts.\(^{77}\) The formation of iPS cells occurs via the dedifferentiation of somatic cells, and this requires shifts in the patterns of expression of thousands of genes.\(^{78,79}\) A single miRNA can influence many hundreds of genes, and as such, there has been much interest in their possible role in forming iPS cells. Indeed several reports have shown that miRNAs can promote the formation of iPS cells either alone\(^{80,81}\) or in combination with the OKSM factors.\(^{82}\)

During the process of converting to iPS cells, somatic cells adopt a pluripotent cell cycle phenotype that is characterized by rapid proliferation, a shortened S-phase, and low expression of cell cycle inhibitors, such as p21 and p53\(^{83,84}\). Moreover, activation of the p53-p21 pathway suppresses iPS formation.\(^{85}\) Several miRNAs are involved in ESC proliferation,\(^{86}\) and they have been exploited to generate iPS cells. MiRNA-302d, miRNA-291, miRNA-294, and miRNA-295 promote proliferation in ESCs. For example, when ectopically expressed in ESCs lacking the miRNA microprocessor subunit Dgcr8 (DiGeorge Syndrome Critical Region 8), which lack canonical miRNAs and proliferate slowly, miRNA-302d, miRNA-291, miRNA-294, and miRNA-295 reduced the number of cells in G1 to that typically found in wild-type ESCs\(^86\) by specifically targeting p21\(^{86}\) and retinoblastoma-like 2 protein.\(^{87,88}\) MiRNA-291-3p, miRNA-294, and miRNA-295 are potentially downstream effectors of cMyc and act as a substitute for this transcription factor. The reprogramming efficiency of Oct4, Sox2, and Klf4 was increased by miRNA-291-3p, miRNA-294, and miRNA-295 or cMyc. However, there was no additive effect when the miRNAs and cMyc were used together.\(^{89}\) Similarly, the human orthologs hsa-miRNA-372 and hsa-miRNA-302b promoted reprogramming in human foreskin and lung fibroblasts, expressing OKSM.\(^{82}\) Members of the let-7 miRNA family, which are highly expressed in somatic cells, oppose the effects of miRNAs involved in ESC proliferation.\(^{90}\) Knockdown of let-7 miRNA by an antisense RNA inhibitor promoted the dedifferentiation of murine embryonic fibroblasts (MEFs) to iPS when OKSM were overexpressed.\(^{90}\) Inactivation of miRNA targets of the cell cycle inhibitor p53 also enhances reprogramming efficiency. MiRNA-199a-3p is upregulated by p53 at the post-transcriptional level; induction of this miRNA significantly decreases reprogramming efficiency by arresting cells in G1. Moreover, miRNA-199a-3p inhibition partially rescues iPS generation impaired by p53.\(^{91}\) The expression of the miRNA-34 family is also p53-dependent.\(^{92}\) MiRNA-34a, a member of the miRNA-34 family, represses iPS reprogramming by acting in concert with p21 to suppress expression of Nanog, Sox2, and N-Myc.\(^{93}\) The expression of p53 is controlled by miRNAs, and this information has been used to augment reprogramming efficiency. For example, miRNA-138 enhances reprogramming to iPS by binding to the 3′ untranslated region of p53 and decreasing the expression of the protein.\(^{94}\) Moreover, depletion of 2 MEF-enriched miRNAs, miRNA-21 and miRNA-29a, enhances reprogramming efficiency in part through reduced p53 expression.\(^{95}\)

MiRNAs also influence the mesenchymal-to-epithelial transition that occurs in the initiation stage of reprogramming by
modulating the transforming growth factor (TGF-β) signaling pathway. The TGF-β receptor-2 protein is a specific target of 2 miRNA clusters, miRNA-106b/25 and miRNA-302/367. Overexpression of the miRNA-302/367 cluster6,97 or 2 components of miRNA-106b/25 cluster, miRNA-93 and miRNA-106b,98 accelerates the mesenchymal-to-epithelial transition and increases the number of iP cells derived from MEFs expressing OKSM or OKS. The miRNA-302/367 cluster (miRNA-302a/b/c/d and miRNA-367), in addition to its role in regulating TGF-β signaling, targets the bone morphogenetic protein inhibitors TOB2, DAZAP2, and SLAIN1.99 The bone morphogenetic protein and TGF-β signaling pathways converge on Smad proteins, suggesting that miRNA-302/367 could potentially promote reprogramming via these proteins. Cross-talk between TGF-β and cell proliferation pathways also exists. One study, using a library screen, found that the miRNA-130/301/721 family promoted generation of iP cells by inhibiting expression of mesenchyme homeobox 2.100 TGF-β suppresses endothelial cell growth through activation of mesenchyme homeobox 2, which in turn triggers expression of p21.101

Chromatin remodeling influences the ability of miRNAs to reprogram somatic cells into iP cells. Considerable epigenetic changes occur during reprogramming,102 and pharmacological inhibition of key chromatin modifiers, such as histone deacetylases and DNA methyltransferases, increase the efficiency of reprogramming.103,104 Histone deacetylase 2 suppression by valproic acid or genetic ablation allows the miRNA-302/367 cluster, a direct target of Oct4 and Sox2,105 to reprogram MEFs into iP cells without the need for transcription factors.81 Similarly, human foreskin fibroblasts which naturally express low levels of histone deacetylase 2 were reprogrammed to iP cells by expression of the miRNA-302/367 cluster in the absence of valproic acid.81 Elevating the expression of a single miRNA, miRNA-302, to a level 1.3-fold above that found in human ESCs was sufficient to reprogram human hair follicle cells to iP cells.106 MiRNA-302 reprogramming to iP cells required the repression of several epigenetic regulators, such as the lysine-specific demethylases AOF1 and AOF2, as well as the methyl-CpG-binding proteins MECP1-p66 and MECP2.106 Apoptosis and senescence have also been proposed as possible mechanisms by which miRNAs regulate reprogramming to iP cells; however, definitive roles have not been currently established.107 Moreover, direct regulation of the OKSM factors is another putative mechanism. MiRNA-25 directly regulates Wwp2, an E3 ubiquitin ligase that targets Oct4 for ubiquitination, and Fbxw7, which is known to regulate c-Myc. By increasing levels of Oct4 and c-Myc, miRNA-25 was found to promote the formation of iP cells.108

To summarize, miRNAs are important tools for reprogramming somatic cells to iP cells. However, the similarity between miRNA and transcription factor reprogrammed iP has not been studied and differences may exist in the iP generated by the 2 methods.

**MiRNAs, iP, ESCs, and the Acquisition of a Cardiac Phenotype**

Several microRNAs, including miRNA-1, miRNA-133, miRNA-208, and miRNA-499, have also been used to drive cardiac differentiation in ESCs and iP cells.109,110 In a 2D ESC culture model, levels of miRNA-1 and miRNA-133 were reduced following forced myocardial differentiation by trichostatin-A, a histone deacetylase inhibitor.111 Moreover, overexpression of miRNA-1 or miRNA-133 by lentivirus reduced the expression of Nkx2.5, with miRNA-1 also inhibiting expression of αMHC. CDK9 was proposed to be involved in the pathway based on the finding that miRNA-1 reduced protein expression by targeting the 3’ untranslated region of the CDK9 mRNA,111 as well as previous work by the authors, which showed that CDK9 formed a transcriptional complex with p300/Gata4 to activate expression of Nkx2.5, ANF, and β-MHC.112 In support of these studies, overexpression of the drosophila miRNA-1 homolog in cardiac mesoderm resulted in fewer cardiac cells.113 However, the effects of miRNA-1 and miRNA-133 on ESC cardiac differentiation may be dependent on the model used because the findings with embryoid body–based culture of ESC cells were found to be markedly different.109 Starting from the observation that both miRNA-1 and miRNA-133 were highly expressed in ESC-derived cardiomyocytes, the authors found that expression of miRNA-1 or miRNA-133 in embryoid body promoted mesoderm gene expression at the expense of ectoderm and endoderm differentiation. Moreover, although miRNA-1 promoted further differentiation toward a cardiac or skeletal muscle fate, miRNA-133 was inhibitory. The Notch ligand, delta-like 1, was translationally repressed by miRNA-1, and indeed knockdown of delta-like 1 recapitulated the miRNA-1 overexpression phenotype in ESCs.109 Further support for a role of miRNA-1 in the adoption of a cardiomyocyte phenotype has come from studies in Xenopus embryos.42 Misexpression of miRNA-1 strongly inhibited myogenesis by targeting histone deacetylase 4,42 which negatively regulates a protein critical for muscle differentiation, Mef2.114 Moreover, overexpression of miRNA-1 in iP cells led to the expression of cardiac transcription factors and sarcomeric proteins.115 Similarly, in ESC-derived multipotent cardiovascular progenitors, miRNA-1 promoted cardiomyocyte differentiation and suppressed endothelial cell commitment by modulating Wnt and FGF signaling pathways, with frizzled class receptor 7 and far1-related sequence being confirmed as miRNA-1 targets.115

MiRNA-1 may also be involved in the electrophysiologically maturation of ESC-derived cardiomyocytes.116 Lentiviral-mediated delivery of miRNA-1 into human ESC-derived cardiovascular progenitors had no effect on the yield of human ESC-derived ventricular cardiomyocytes. However, hallmarks of maturation were observed, such as decreased action potential duration and hyperpolarized resting membrane potential/maximum diastolic potential. Ca2+ transient amplitude and kinetics were also augmented.116 Irrespective of the in vitro results, overexpression of miRNA-1 has been shown to drive cardiac differentiation of ESCs in vivo.117 When assessed 2 weeks post-MI, injected ESCs expressing miRNA-1 demonstrated enhanced commitment to the cardiomyocyte lineage when compared with control ESCs, and improved cardiac function was noted.117 A paracrine mechanism may also be important in this model because the host myocardium displayed reduced apoptosis through Akt activation and caspase-3 inactivation.117
Levels of miRNA-499 also increase during the differentiation of ESC cells into cardiomyocytes. Overexpression of miRNA-499 in embryoid bodies upregulated αMHC and MeF2C expression. Similarly increasing expression of miRNA-499 in human ESC-derived cardiovascular progenitors significantly augmented the yield of ventricular cardiomyocytes and contractile protein expression without affecting electrophysiological properties.

MiRNA-363 is involved in ESC-derived cardiac subtype specification. Screening for miRNAs that potentially affected Hand1 and 2, genes involved in left and right ventricular development respectively, identified miRNA-363 as a candidate. Over-expression of miRNA-363 reduced Hand1 mRNA levels, and suppression of this miRNA led to an enrichment of left ventricular ESC-derived cardiomyocytes.

MiRNAs and Direct Cardiac Reprogramming

Development of MiRNA Combo for the Transdifferentiation of Fibroblasts to Cardiomyocytes

Based on their roles in cardiac development, our laboratory hypothesized that miRNAs would be capable of reprogramming fibroblasts directly into cardiomyocytes. We selected 6 candidate miRNAs, miRNA-1, miRNA-126, miRNA-133a, miRNA-138, miRNA-206, and miRNA-208a, based on their function in cardiac muscle development and differentiation.9,47,55,119–121 Adapting a combinatorial approach, we identified that miRNA-1 and the combination of miRNA-1, miRNA-133a, and miRNA-208a induced the expression of early markers of commitment to the cardiomyocyte lineage. Though miRNA-1 alone was found to be sufficient to drive cardiac gene expression, efficiency was higher in combination with miRNA-133a and miRNA-208a. Further studies showed that the addition of miRNA-499 further augmented the efficiency of cardiac reprogramming.9 This combination of miRNAs, miRNA-1, miRNA-133a, miRNA-208a, and miRNA-499, we named miR combo. A single transient transfection of miR combo was found to be sufficient to induce fibroblasts to express cardiac markers, such as MeF2C and αMHC.5,10 The initial steps of reprogramming were relatively rapid in vitro. Mature cardiomyocyte markers, such as αMHC and cardiac troponins, were observed $\approx$7 days after transfection. Full maturation of the reprogrammed cells was observed only after prolonged culture. Approximately 4 weeks after transfection, organized sarcomeres, contraction, and spontaneous calcium transients were observed.9

miR Combo Regenerates the Heart: Reprogramming and the Correlation Between Maturation and Functional Improvement

In a proof-of-principle experiment, we used the Fsp1Cre:tdTomato (tandem dimer Tomato) model to validate reprogramming of fibroblasts in vivo. In this model, the tdTomato protein permanently labels fibroblasts. Lentiviruses encoding for the individual miRNAs in the miR combo were injected into ischemic myocardium. One month after myocardial injury, tdTomato+cardiomyocytes were observed, which provided evidence of direct reprogramming of fibroblasts in situ.9 We found that 1 month post-MI, tdTomato+cardiomyocytes represented $\approx$1% of the infarct border zone, and 2 months post-MI, the number of tdTomato+cardiomyocytes had risen to $\approx$10%.9,11 We observed that miR combo promoted a progressive improvement in cardiac function over a 3-month period associated with reduced fibrosis after MI.11 The improvement of cardiac function by miR combo occurred in the absence of any effects on cardiomyocyte apoptosis and de novo vascularization. Thus, the effect of miR combo in vivo on cardiac function was both progressive and time-delayed. This has also been observed with reprogramming strategies involving transcription factors. Based on our in vitro observation of time taken from reprogramming to cell maturation, we hypothesized that the delay in cardiac functional improvement in vivo is in part as a result of the time taken for reprogrammed fibroblasts to fully mature into cardiomyocytes and integrate into the myocardium. Indeed, at 2 months, the reprogrammed tdTomato+cardiomyocytes expressed cardiomyocyte markers, sarcomeric organization, excitation–contraction coupling, and action potentials characteristic of maturing ventricular tdTomato–cardiomyocytes.11 Taken together, our findings suggest a correlation between maturation of reprogrammed cardiomyocytes and improved cardiac function (Figure 1A). Fully establishing that full maturation of reprogrammed fibroblasts into cardiomyocytes underlies the improvements in cardiac function will require a systematic study of the temporal effects of miR combo treatment at the cellular and functional level in conjunction with statistical modeling.

Maturation: Why Is There More In Vivo?

Reprogramming with miR combo is more efficient in vivo than in vitro. Why this is the case is currently unknown. It is possible that other cell types in the heart, cardiomyocytes and cardiac progenitor cells, influence reprogramming either through the release of paracrine factors or by cell:cell communication through adherens junctions. We anticipate that paracrine factors will play a particularly important role. In the past decade, substantial evidence has been provided to support the notion that stem cells exert their reparative and regenerative effects, in large part, through the release of biologically active molecules acting in a paracrine fashion on resident cells.122 Pertinent to this review, we have recently identified that a paracrine factor released by mesenchymal stem cells, Abi3bp, promotes cardiac progenitor cell differentiation.123 Tissue engineers have sought to recapitulate the native cardiac environment. They have had notable successes in generating cardiac tissue,124 and their findings potentially shed light on the question of why maturation of miR combo–reprogrammed fibroblasts is more efficient in vivo. What they have found is that 3D environments, decellularization of organs which leaves extracellular matrix intact, and stimulation, whether it be mechanical or electric, promote the formation of cardiac tissue.124 Thus, we hypothesize that components of the extracellular matrix, mechanical forces, and the cell shape in the 3D environment is important (Figure 1B) for the maturation of miR combo reprogrammed cells. These mechanisms would promote maturation either by increasing the rate of the initial reprogramming event or by directly affecting the expression of mature cardiac structural and functional proteins.
Mechanisms for Direct Reprogramming of Cardiac Fibroblasts by miR Combo

Knowledge of the mechanistic basis for the reprogramming of cardiac fibroblasts into cardiomyocytes by transcription factors or miRNAs is currently lacking. The epigenetic landscape of cardiac fibroblasts is likely to be different to that of cardiomyocytes; such differences are believed to be important for the maintenance of a differentiated phenotype. Differences between the epigenetic landscape of cardiac fibroblasts and cardiomyocytes would be expected to be a significant barrier to direct reprogramming. The transcription factors currently used, such as Mef2C, Gata4, and Tbx5 (GMT), are known to be important for the development of heart. However, how these transcription factors access the silent promoters of cardiac genes in fibroblasts is currently unknown; presumably they act as pioneer transcription factors that recognize their target sites irrespective of the preexisting chromatin state. Considering that the epigenetic landscape represents a molecular roadblock to reprogramming, we conducted a genetic screen to identify epigenetic modifiers regulated by miR combo. We found that miRNA combo downregulates expression of the histone lysine N-methyltransferase Setdb2, a protein which specifically trimethylates lysine-9 of histone H3. Considering that trimethylates lysine-9 of histone H3 is associated with transcriptional repression, our data indicates that miR combo induces reprogramming by alleviating the suppression of cardiac genes in fibroblasts (unpublished data). Future work is necessary to determine which constituent of cardiac genes in fibroblasts is currently unknown; presumably they act as pioneer transcription factors that recognize their target sites irrespective of the preexisting chromatin state.

Figure 1. Schematic describing the hypothesis that the time-delayed improvements in cardiac function are dependent on the maturation of reprogrammed cells. A, The cardiac function data (fractional shortening) vs time are derived from Jayawardena et al.11 The upper panel depicting the progression of transdifferentiation (with specific cardiac gene expression) to maturation is based partly on data11 and partly on hypothesis. B, The putative factors influencing cardiomyocyte maturation in vivo: paracrine factors released by other cardiac cells, the composition of the ECM, mechanical forces and cell:cell communication. Mef2 indicates myocyte enhancer factor; MHC, myosin heavy chain; and miR, microRNA.

Figure 2. MicroRNAs (miRNAs/miR) and reprogramming. miRNAs promote the generation of cardiomyocytes via several mechanisms. Fibroblasts (FB) can be reprogrammed into cardiomyocytes (CM) by miRNAs directly or through an intermediate inducible pluripotent stem (iPSC) state. miRNAs also promote cardiac progenitor cell (CPC) and embryonic stem cell (ESC) cardiac differentiation. miRNAs can promote or inhibit cardiomyocyte proliferation.
miR combo downregulates Setd2 expression, as well as the possible role of other epigenetic modifications in mediating the effects of miR combo.

Enhancing Direct Reprogramming by Combining miRNA and Transcription Factor Strategies

Other researchers have used miRNA-1 and miRNA-133 in combination with transcription factors to increase the efficiency of mouse and human fibroblast reprogramming into cardiomyocytes in vitro. Nam et al were able to drive expression of cardiac markers in neonatal and human fibroblasts using miRNA-1, miRNA-133, Gata4, Hand2, Tbx5, and myocardin. Four to 11 weeks after transfection, sarcomeric-like structures and calcium transients were observed, with several cells showing spontaneous contractility.126 Gata4, Hand2, Tbx5, myocardin, and Mef2C were originally identified as being able to reprogram fibroblasts into cardiomyocytes. Retrospective expression of miRNA-1 and miRNA-133 increased the number of cardiac troponin-T-positive cells. Curiously, removal of Mef2C enhanced reprogramming.126 Underlying the importance of miRNA-133, genetic ablation of this miRNA reduced the number of cardiac troponin-T-positive cells to almost background levels.126 The authors speculated that miRNA-1 and miRNA-133 were important for the development of sarcomeres and suppressed myocardin activation of smooth muscle differentiation.116 miRNA-133, in combination with GHT, has also been shown to be important in the acquisition of a cardiac phenotype in MEFs.127 Overexpression of miRNA-133, in combination with GHT, increased by >5-fold the number of MEFs expressing α-sarcomeric actinin, αMHC, and cardiac troponin-T when compared with cells expressing GHT alone. Similar results were obtained with the number of beating cells, and the time taken for maturation was found to be significantly shortened.127 The authors showed that miRNA-133 enhanced GHT reprogramming by silencing fibroblast markers via suppression of the epithelial-to-mesenchymal transition regulator Snai1.127

MiRNAs and Adult Cardiac Stem Cells

The heart contains resident cardiac progenitors, which can potentially form all the major cell types of the heart, including cardiomyocytes, endothelial cells, and smooth muscle.128 In 2 recent clinical trials, SCIPIO and CADUCEUS, cardiac progenitor cells have demonstrated their therapeutic potential.129,130 Strategies are needed to drive cardiac progenitor differentiation toward the cardiomyocyte lineage, especially because currently this is inefficient. Despite the potential benefits of miRNAs to direct cardiac progenitor fate, a relatively limited number of reports have been published regarding their use in this regard.

Transient transfection of miRNA-1 and miRNA-499 into cardiac progenitors derived from human fetuses reduced cell proliferation and enhanced differentiation to cardiomyocytes; for example, reducing the time taken for spontaneously beating clusters to appear from 21 to 7 days.131 The effects of miRNA-1 and miRNA-499 were likely as a result of the repression of histone deacetylase 4 or Sox6. Indeed, siRNA mediated knockdown of Sox6-induced cardiomyocyte differentiation.131 The results with miRNA-499 were confirmed by a separate study using c-Kit+ cardiac progenitors.132 Here, the authors went one step further and injected cardiac progenitors expressing miRNA-499 into infarcted hearts. Increased cardiomyogenesis was observed with an elevated cardiomyocyte mass.132 The authors also identified a novel mechanism by which miRNA-499 can influence cardiac progenitor behavior. MiRNA-499 was found to translocate from C2C12 myoblasts to recipient cardiac progenitor cells via gap junctions between the 2 cell types. The function of the miRNA-499 was preserved after gap junction transfer to cardiac progenitors, and this favored their differentiation into functionally competent cardiomyocytes.132 MiRNA-1 is also important for the control of cardiac progenitor cell polarity during development in drosophila.133 Cell polarity is known to play multiple roles in cardiac differentiation and development.134 MiRNAs are also involved in inhibiting differentiation. For example, miRNA-590 and miRNA-155 have opposing effects on cardiac progenitor differentiation. TGF-β1 promotes differentiation of cardiosphere-derived cells by the downregulation of miRNA-590.135 MiRNA-155 inhibits Sca-1+ cardiac progenitor cell differentiation by downregulating β-arrestin-2.136

Differentiation of cardiac progenitors requires a halt in proliferation. Sirish et al compared miRNA expression profiles in c-Kit+ cardiac progenitors derived from neonatal and adult hearts. When compared with adult cells, neonatal c-Kit+ cardiac progenitors expressed higher levels of the proliferation marker Ki67 with a 7-fold higher doubling time. MiRNA-17 was also elevated in neonatal c-Kit+ cardiac progenitors, and as a proof-of-principle expression of the miRNA-17-92 cluster in adult, c-Kit+ progenitors increased their proliferation rate. The antiproliferative cell cycle protein retinoblastoma-like 2 (Rbl2/p130) was proposed as a target for miRNA-17 on the basis of an interaction site within the 3′ untranslated region; though Rbl2/p130 miRNA levels were not significantly different, protein levels were significantly lower in neonatal c-Kit+ cardiac progenitor cells when compared with adult cells.137 MiRNA-10a reduces cardiac progenitor cell proliferation by targeting Gata6.138

In summary, several microRNAs have been identified that regulate key aspects of cardiac progenitor biology. However, it is clear that more studies are necessary to fully characterize the full complement of microRNAs that influence cardiac progenitor differentiation and proliferation.

Future Perspectives

The studies described in this review highlight the fundamental role that miRNAs play in cardiac reprogramming, differentiation, and development (Figure 2). Based on the understanding of above, we hypothesize that targeting specific miRNAs is a rational strategy for cardiac regenerative therapy. MiRNA-based therapy can be used to promote cardiomyocyte proliferation, reprogram directly fibroblasts to cardiomyocytes or indirectly to iPSC, as well as driving the differentiation of iPSCs, ESCs, or CPCs to cardiomyocytes (Figure 2).

Key issues need to be addressed before miRNAs can be taken into the clinic. One such question is the combination of miRNAs that will induce cardiac regeneration. Species
differences between mouse and human are likely to necessitate a different combination of miRNAs for efficient proliferation and direct or indirect reprogramming. Another question is how these miRNAs will be delivered into the patient. There are several options, such as viral delivery or chemical modification. Lentiviral- and retrovirus-based strategies may be appropriate because a single miRNA can influence multiple pathways at once. By virtue of their small size, miRNAs can be packaged into a virus, and miRNAs are smaller DNA molecules than transcription factor genes. Currently, the in vivo use of transcription factors for reprogramming has relied on retroviruses containing a single transcription factor. Another potential issue is the expression of multiple genes from a single DNA cassette; the genes do not necessarily express at similar levels, and this could seriously affect reprogramming efficiency. Naturally occurring multicistronic miRNA constructs can be modified to express any miRNA combination of choice. For example, modification of the endogenous miRNA-17-92 cluster to express miRNAs that target the hepatitis C viral genome prevents replication of the hepatitis C virus.

This has been used to inhibit hepatitis C virus replication, for example, by modifying packaging DNA into viral vectors because of their small size.

AntagomiRs, miRNAs modified with cholesterol or phosphorothioate moieties to increase their stability in vivo, have been used to reduce the expression of miRNAs that mediate pathology after myocardial injury. AntagomiRs may also prove to be a useful ally for cardiac reprogramming. It is well known that there are significant barriers to reprogramming. Cell type–specific miRNAs prevent translation of lineage-inappropriate miRNAs. Targeting these cell type–specific miRNAs with antagomiRs is likely to enhance cardiac reprogramming.

Cardiomyocyte proliferation, differentiation, and reprogramming involve the co-ordinated action of many proteins acting in multiple pathways. For this reason, all of the many strategies used for reprogramming, miRNAs offer the most appropriate route because a single miRNA can influence multiple pathways at once. By virtue of their small size, miRNAs are ideal for adenoviral-associated virus–based therapies, which have generated much interest because of their inherent safety. Finally, by adapting naturally occurring multicistronic miRNA constructs, researchers have the ability to nuance the expression of reprogramming miRNAs, which is important for dosing concerns.

Sources of Funding
This work was supported by National Heart, Lung, and Blood Institute grants RO1 HL81744, HL72010, and HL73219 (to VJ, Dzau) and the Edna and Fred L. Mandel Jr Foundation (to VJ, Dzau and M. Mirotou). M. Mirotou was also supported by an American Heart Association National Scientist Development Award (10SDG4280011).

Disclosures
None.

References


